[1] Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Hou JL, et al. The guideline of prevention and treatment for chronic hepatitis B: a 2015 update. Chin J Hepatol, 2015; 23, 888−905. (In Chinese
[2] Jia JD, Zhuang H. Join hands to promote the accessibility of chronic hepatitis B treatment in China. Chin Hepatol, 2016; 21, 239−40. (In Chinese
[3] Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease: the major impact of China. Hepatology, 2014; 60, 2099−108. (In Chinese doi:  10.1002/hep.27406
[4] Li MH, Zhang D, Zhang L, et al. Ratios of T-helper 2 Cells to T-helper 1 cells and cytokine levels in patients with hepatitis B. Chin Med J, 2017; 130, 1810−5. doi:  10.4103/0366-6999.211541
[5] Li MH, Chen QQ, Zhang L, et al. Association of cytokines with hepatitis B virus and its antigen. J Med Virol, 2020; 92, 3426−35. doi:  10.1002/jmv.26301
[6] Li MH, Zhang L, Zhang D, et al. Plasmacytoid dendritic cell function and cytokine network profiles in patients with acute or chronic hepatitis B virus infection. Chin Med J, 2018; 131, 43−9. doi:  10.4103/0366-6999.221275
[7] Cao WH, Li MH, Pan CQ, et al. Quantitation of plasmacytoid dendritic cells in chronic hepatitis B patients with HBeAg positivity during PEG-IFN and entecavir therapy. J Int Cytokine Res, 2018; 38, 197−205. doi:  10.1089/jir.2018.0014
[8] Li MH, Lu Y, Zhang L, et al. Association of cytokines with alanine aminotransferase, hepatitis B virus surface antigen and hepatitis B envelope antigen levels in chronic hepatitis B. Chin Med J, 2018; 131, 1813−8. doi:  10.4103/0366-6999.237394
[9] European Association for the Study of the Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol, 2015; 63, 237−64. doi:  10.1016/j.jhep.2015.04.006
[10] Li M, Wang ZQ, Zhang L, et al. Burden of cirrhosis and other chronic liver diseases caused by specific etiologies in China, 1990-2016: findings from the global burden of disease study 2016. Biomed Environ Sci, 2020; 33, 1−0.
[11] Chen H, Liu N, Ji ZH, et al. Assessment on the effects of hepatitis B prevention and control measures in western China: a comparison of three population-based serosurveys. Biomed Environ Sci, 2020; 33, 735−44.
[12] Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology. The guidelines of prevention and treatment for chronic hepatitis B (2019 version). Chin J Hepatol, 2019; 27, 938−61. (In Chinese
[13] Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology, 2018; 67, 1560−99. doi:  10.1002/hep.29800
[14] Li MH, Zhang L, Qu XJ, et al. Kinetics of hepatitis B surface antigen level in chronic hepatitis B patients who achieved hepatitis B surface antigen loss during pegylated interferon Alpha-2a treatment. Chin Med J, 2017; 130, 559−65. doi:  10.4103/0366-6999.200554
[15] Li MH, Yi W, Zhang L, et al. Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha-based therapy. J Viral Hepat, 2019; 26, 32−41. doi:  10.1111/jvh.13151
[16] Li MH, Zhang L, Qu XJ, et al. The predictive value of baseline HBsAg level and early response for HBsAg loss in patients with HBeAg-positive chronic hepatitis B during pegylated interferon Alpha-2a treatment. Biomed Environ Sci, 2017; 30, 177−84.
[17] Fu WK, Cao J, Mi NN, et al. Cytokines predict virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy. World J Clin Cases, 2020; 8, 2255−65. doi:  10.12998/wjcc.v8.i11.2255
[18] Liu RY, Chen YH, Guo J, et al. The reduction in CD8+PD-1+ T cells in liver histological tissue is related to Pegylated IFN-α therapy outcomes in chronic hepatitis B patients. BMC Infect Dis, 2020; 20, 590. doi:  10.1186/s12879-020-05320-z
[19] Yan H, Zhang X, Lv Y. The effect of entecavir therapy on immune status in chronic hepatitis B patients. Iran J Immunol, 2019; 16, 84−91.
[20] Li L, Jing YB, Liu J, et al. Study on the correlation of the effect of entecavir on Th1/Th2 cytokines level in the treatment of chronic hepatitis. Chin J Hepatol, 2017; 25, 606−11. (In Chinese
[21] Viganò M, Grossi G, Loglio A, et al. Treatment of hepatitis B: Is there still a role for interferon. Liver Int, 2018; 38, 79−83. doi:  10.1111/liv.13635
[22] Zografos TA, Liaskos C, Rigopoulou EI, et al. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C. Am J Gastroenterol, 2008; 103, 605−14. doi:  10.1111/j.1572-0241.2007.01729.x
[23] Arababadi MK, Bidaki MZ, Kennedy D. IL-17A in hepatitis B infection: friend or foe. Arch Virol, 2014; 159, 1883−8. doi:  10.1007/s00705-014-2002-x
[24] Dewidar B, Meyer C, Dooley S, et al. TGF-β in hepatic stellate cell activation and liver fibrogenesis-updated 2019. Cells, 2019; 8, 1419. doi:  10.3390/cells8111419
[25] Fisicaro P, Rossi M, Vecchi A, et al. The good and the bad of natural killer cells in virus control: perspective for Anti-HBV therapy. Int J Mol Sci, 2019; 20, 5080. doi:  10.3390/ijms20205080
[26] Li MH, Zhang L, Lu Y, et al. Early serum HBsAg kinetics as predictor of HBsAg loss in patients with HBeAg-Negative chronic hepatitis B after treatment with pegylated interferonα-2a. Virol Sin, 2021; 36, 311−20. doi:  10.1007/s12250-020-00290-7